ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2819

The Transcription Factor MAF Controls the Ability of T Peripheral Helper (Tph) Cells to Help B Cells

Alexandra Bocharnikov1, Vanessa Wacleche 1, Ye Cao 1 and Deepak Rao 2, 1Brigham and Women's Hospital, Boston, 2Brigham and Women's Hospital, Boston, MA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: B cells, systemic lupus erythematosus (SLE) and cytokines, T cells

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T117: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (2816–2821)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Pathologic T cell-B cell interactions are hallmark features of many autoimmune diseases. PD-1hi CXCR5- T peripheral helper (Tph) cells are B cell-helper T cells that are highly expanded in the joints of seropositive RA patients and in the circulation of SLE patients. Like T follicular helper (Tfh) cells, Tph cells produce IL-21 and stimulate B cell differentiation into plasmablasts in vitro. B cell helper-function is often considered dependent on the transcription factor Bcl6, a master regulator of Tfh-cells. However, Tph cells do not express high levels of Bcl6, which suggests that transcription factors other than Bcl6 may control IL-21 production and B cell-helper function in human CD4+ T cells. Here we evaluated the role of the transcription factor MAF in controlling T cell help to B cells.

Methods: MAF expression in human CD4+ T cell subsets was determined by RNA-seq and flow cytometry. To evaluate the role of MAF, we disrupted the gene encoding MAF by nucleofection of a CRISRP/Cas9 ribonucleoprotein (RNP) complex in primary CD4+ T cells and in sorted Tph cells. Expression of IL-21 and other cytokines was determined by RT-PCR and ELISA. B cell-helper function of CRISPR-treated T cells was evaluated by co-culturing sorted T cell subsets from SLE or control donors with memory B cells plus SEB. Plasmablast formation was determined by flow cytometry.

Results: RNA-seq analyses of CD4+ T cell subsets revealed high expression of MAF, but not BCL6, in both Tph cells and Tfh cells sorted from blood of RA and SLE patients (Fig. 1A). After 2 days of CD3/CD28 stimulation, Tph cells and Tfh cells expressed >2-fold higher levels of MAF protein than did naive or PD-1neg memory CD4+ T cells. High expression of MAF in both Tph cells and Tfh cells, two subsets that produce IL-21, suggested a possible connection between MAF and IL-21. To test this, we deleted MAF in primary human CD4+ T cells by nucleofection of a MAF-targeting CRISPR/Cas9 RNP. This method abrogated MAF protein expression in >80% of T cells. Compared to a control CRISPR targeting CD8, MAF deletion reduced mRNA expression of IL21 and IL10 in 4 independent donors and inhibited secretion of IL-21 protein (Fig. 1B). Using Tph cells sorted from blood of SLE patients, we confirmed that Tph cells stimulate differentiation of memory B cells into plasmablasts in an IL-21-dependent manner, as neutralization of IL-21, but not IL-10, inhibited plasmablast formation by ~50%. To evaluate the effect of MAF on B cell-helper function, we deleted MAF by CRISPR in sorted human Tph cells from SLE patients or controls and then co-cultured these cells with memory B cells. Deletion of MAF reduced the ability of Tph cells to induce B cell differentiation into plasmablasts by over 50% compared Tph cells treated with a control RNP (Fig. 1C).

Conclusion: High expression of MAF is a common feature of both Tph cells and Tfh cells, two T cell populations that produce high levels of IL-21. Loss of MAF inhibits IL-21 expression in primary human CD4+ T cells and abrogates the ability of Tph cells to help B cells. MAF may regulate key components of T cell help to B cells in autoimmune conditions.

Figure 1: The role of MAF in human Tph cell function.
A- MAF and Bcl6 expression in RNA-seq data of T cell subsets sorted from blood of RA -n=5- and SLE -n=6- patients. B- Reduced IL-21 mRNA expression -left- and protein secretion -right- by primary human CD4+ T cells after CRISPR-deletion of MAF -n=4 donors-. C- Plasmablast generation in co-cultures of Tph cells treated with MAF- or CD8-targeting complexes co-cultured with allogeneic memory B cells. *p<0.05 by paired t-test.


Disclosure: A. Bocharnikov, None; V. Wacleche, None; Y. Cao, None; D. Rao, Janssen, 5, Merck, 2, Pfizer, 5.

To cite this abstract in AMA style:

Bocharnikov A, Wacleche V, Cao Y, Rao D. The Transcription Factor MAF Controls the Ability of T Peripheral Helper (Tph) Cells to Help B Cells [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/the-transcription-factor-maf-controls-the-ability-of-t-peripheral-helper-tph-cells-to-help-b-cells/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-transcription-factor-maf-controls-the-ability-of-t-peripheral-helper-tph-cells-to-help-b-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology